
Costs for epilepsy medications in the United States are skyrocketing, outpacing inflation and straining federal insurers Medicare and Medicaid, according to new research. Spending on antiseizure medications more than doubled in eight years for the government insurers, largely because of third-generation and brand-name drugs, the study found. “While it’s very important that Medicare and Medicaid… read on > read on >